Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug 28;15(8):e0238288.
doi: 10.1371/journal.pone.0238288. eCollection 2020.

Prognostic value of copeptin in patients with acute coronary syndrome: A systematic review and meta-analysis

Jiapeng Lu  1 , Siming Wang  1 , Guangda He  1 , Yanping Wang  1
Affiliations
Meta-Analysis

Prognostic value of copeptin in patients with acute coronary syndrome: A systematic review and meta-analysis

Jiapeng Lu et al. PLoS One. .

Abstract

Background: The aim of this study was to evaluate the value of copeptin in predicting mortality including both short-term and long-term mortality in patients with acute coronary syndrome (ACS).

Methods: Potential studies were searched and selected through PubMed, Embase and Cochrane databases up to December 2019. The predictive performance was evaluated by the pooled sensitivity and specificity, and summary receiver operating characteristic curves. Cochran's Q test and I2 index were used to assess between-study heterogeneity, and Deek's test and funnel plots were used to assess publication bias.

Results: Total six studies comprising 2269 patients were included in this meta-analysis. The area under the receiver operating characteristic curve of copeptin in predicting mortality in patients with ACS was 0.73 (95% CI: 0.69-0.77). The pooled sensitivity and specificity of copeptin were 0.77 (95% CI: 0.59-0.89) and 0.60 (95% CI: 0.47-0.71), respectively. Significant between-study heterogeneity was identified in both sensitivity (P = 0.01; I2 = 69.76%) and specificity (P<0.001; I2 = 97.32%) among the six included studies. The meta-regression analysis indicated that the number of study centers was significantly associated with the heterogeneity of sensitivity (P = 0.03), whereas the study design (P = 0.03) and duration of follow-up (P<0.001) were significantly associated with the heterogeneity of specificity.

Conclusions: Copeptin has acceptable prognostic value for mortality in patients with ACS. Further studies based on multimarker strategy are needed to evaluate the prognostic value of copeptin for ACS in conjunction with other well-established biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart of study selection.
ACS: acute coronary syndrome.
Fig 2
Fig 2. Quality assessment of included studies using QUADAS-2.
Fig 3
Fig 3. Summary receiver operating characteristic curve of copeptin in predicting mortality in patients with acute coronary syndrome.
Fig 4
Fig 4. Forest plot of the sensitivity and specificity of copeptin in predicting mortality in patients with acute coronary syndrome.
Fig 5
Fig 5. Funnel plot for detecting publication bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ma Q, Wang J, Jin J, Gao M, Liu F, Zhou S, et al. Clinical characteristics and prognosis of acute coronary syndrome in young women and men: A systematic review and meta-analysis of prospective studies. International journal of cardiology. 2017;228:837–43. 10.1016/j.ijcard.2016.11.148 - DOI - PubMed
    1. Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, et al. One-year clinical outcome of interventionalist- versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study. Circulation Cardiovascular quality and outcomes. 2011;4(3):355–62. 10.1161/CIRCOUTCOMES.110.958785 - DOI - PubMed
    1. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. European heart journal. 2014;35(6):365–75. 10.1093/eurheartj/eht218 - DOI - PubMed
    1. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European heart journal. 2012;33(16):2001–6. 10.1093/eurheartj/ehq509 - DOI - PubMed
    1. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology: JGC. 2017;14(2):135–50. 10.11909/j.issn.1671-5411.2017.02.008 - DOI - PMC - PubMed

Publication types